SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 25, 2002
ENZON, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-12957 22-2372868
(State or other jurisdiction of (Commission (IRS Employer
incorporation) File Number) Identification)
20 Kingsbridge Road, Piscataway, New Jersey 08854
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (732) 980-4500
NA
(Former name or former address, if changed since last report
Item 5. Other Events
On February 25, 2002, Enzon, Inc. (the "Company") announced the appointment
of Robert Parkinson, Jr. to its Board of Directors.
Last year, Mr. Parkinson retired from Abbott Laboratories ("Abbott"), where
he served as Abbott's President and Chief Operating Officer and served on its
Board of Directors. Prior to his most recent role with Abbott, Mr. Parkinson
served as Executive Vice President, responsible for overseeing Abbott's
international operations for pharmaceutical, hospital and nutritional products,
as well as the U.S.-based Ross Laboratories division.
Mr. Parkinson joined Abbott in 1976 and over a distinguished 25-year career
he served in numerous management capacities, including President, International
Division; President, Chemical and Agricultural Products Division; and Corporate
Vice President European Operations, International Division.
Mr. Parkinson currently serves as Chairman of the Board of GeneProt Inc., a
privately held biotechnology company with operations in Geneva, Switzerland and
North Brunswick, New Jersey. He also serves on the board of directors of
Northwestern Memorial Hospital.
Mr. Parkinson earned both a bachelor's degree and a master's degree in
business administration from Loyola University of Chicago.
Except for the historical information herein, the matters discussed in this
8-K include forward-looking statements that may involve a number of risks and
uncertainties. Actual results may vary significantly based upon a number of
factors, which are described in the Company's Form 10-K, Form 10-Q's and Form
8-K's on file with the SEC, including without limitation, risks in obtaining and
maintaining regulatory approval for indications and expanded indications, market
acceptance of and continuing demand for the Company's products and the impact of
competitive products and pricing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: February 25, 2002
ENZON, INC.
----------------------------------------
(Registrant)
By: /s/ KENNETH J. ZUERBLIS
----------------------------------------
Kenneth J. Zuerblis
Vice President, Finance, Chief Financial
Officer and Corporate Secretary